Market Overview

Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst

Share:
Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst

The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst.

Pfizer, Moderna In The Lead: It now appears that Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), along with its German partner BioNTech SE – ADR (NASDAQ: BNTX), have a two month or more advantage over their nearest rivals among coronavirus vaccine developers, SVB Leerink analyst Geoffrey Porges said in a Wednesday note.

The conviction comes after Dr. Larry Corey, head of the COVID-19 Prevention Network, shared the development timeline and progress of COVID-19 vaccines developed under the White House's Operation Warp Speed at a Tuesday John Hopkins University-University of Washington symposium. 

Of the vaccine developers that have initiated Phase 3 trials, AstraZeneca plc's (NASDAQ: AZN) late-stage trial is still on clinical hold in the U.S. due to safety concerns on transverse myelitis, the analyst said.

Pfizer and BioNTech are expected to read out interim Phase 3 data in late October or early November, and Moderna is expected to read out in early November, Porges said, citing Corey's presentation of the estimated timeline of the clinical trials.

This is based on the differences in dosing and clinical trial design, the analyst said.

Related Link: The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO

J&J Close Behind: The other vaccine sponsor that is likely to have interim results before the end of 2020 is Johnson & Johnson (NYSE: JNJ), Porges said.

This view is based on J&J likely reaching 50 events in December due to its single-dose regimen, the analyst said. 

Vaccines from other manufacturers — including Novavax, Inc. (NASDAQ: NVAX) and Sanofi SA (NASDAQ: SNY) — are a few months behind, likely reading out in the January-April timeframe of 2021, he said. 

"In aggregate it is possible that we will have two or three COVID vaccines approved for Emergency Use in limited indications by year end, and then a further 2 or 3 by the end of Q4, assuming successful interim efficacy read outs and then rapid submission of the EUA application packages by the sponsors," Porges said. 

Even if the interim efficacy analysis results are not positive, necessitating a final event analysis, one or two vaccines could still be approved under emergency use by year's end, the analyst said, followed by J&J's in the first quarter of 2021 and two more in the second quarter.

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Latest Ratings for MRNA

DateFirmActionFromTo
Nov 2020SVB LeerinkMaintainsUnderperform
Nov 2020Wells FargoInitiates Coverage OnEqual-Weight
Nov 2020Chardan CapitalMaintainsBuy

View More Analyst Ratings for MRNA
View the Latest Analyst Ratings

 

Related Articles (PFE + MRNA)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 Geoffrey PorgesAnalyst Color Biotech Health Care Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com